Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib in R/R B-cell Non-Hodgkin Lymphoma
NCT05008055Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of capivasertib in follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), sponsored by AstraZeneca. Started Nov 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05008055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008055.